|
CHECK OUT OUR JANUARY 15TH ISSUE
Two-year results on the first ab interno micro-stent designed to drain into the suprachoroidal space show good efficacy and safety profiles. » Read more
|
|
Data from follow-up to 18 months in a prospective multicenter study of phakic eyes with moderate to advanced glaucoma uncontrolled on two medications show implantation of an ab interno suprachoroidal stent (iStent Supra, Glaukos) and reduction to a single medication provides sustained IOP lowering of at least 10 mm Hg. » Read more
|
|
Combination anti-glaucoma medications used alone or in conjunction with a prostaglandin have substantial IOP-lowering effects. » Read more
|
|
Glaucoma medications should be used judiciously in women of childbearing age as they may pose risks to the infants of pregnant or nursing patients. » Read more
|
|
Although generic medications approved by the FDA are identical to the innovator in their active and inactive ingredients, prescribers must be cognizant about sources of problems associated with the use of ophthalmic generic drugs. » Read more
|
|
The RETAIN Study of the effect of retinal vein occlusion (RVO) treated with ranibizumab injections found good visual acuity results in patients with branch RVO. » Read more
|
|
|
Like
Tweet
